As Ranbaxy’s Regulatory Woes Persist, Imitrex Exclusivity Threatened
This article was originally published in The Pink Sheet Daily
No end in sight for FDA’s import ban on drugs manufactured in Ranbaxy’s Dewas, Paonta Sahib facilities; impact on sales will be felt in 2009.
You may also be interested in...
Ranbaxy may be subject to third-party supervision of its manufacturing of the antiviral ganciclovir, in return for gaining an exception for the product from FDA's Import Alert
Details of tender offer at 40 percent premium revealed.
Revlimid, Copaxone, Sensipar, Enbrel, Acthar Gel and Gleevec will be the subject of a US House Committee on Oversight and Reform in an upcoming drug price hearing.